The efficacy of initial ventilation strategy for adult immunocompromised patients with severe acute hypoxemic respiratory failure: study protocol for a multicentre randomized controlled trial (VENIM)
机构:[1]Emergency Department, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China[2]Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China[3]Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China[4]Emergency Department, Guiyang Second People Hospital, Guiyang, China[5]Department of Science and Technology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China首都医科大学附属天坛医院[6]Department of Ultrasound, Peking Union Medical College Hospital, Beijing, China[7]Department of Emergency, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, China[8]Emergency Department, First Affiliated Hospital of Kunming Medical University, Kunming, China内科科室急诊医学科昆明医科大学附属第一医院[9]Department of Emergency, Renmin Hospital of Wuhan University, Wuhan, China[10]Emergency Department, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[11]Emergency Department, Affiliated Hospital of Guizhou Medical University, Guiyang, China[12]Department of Emergency, The Second Affiliated Hospital of Harbin Medical University, Harbin, China[13]Department of Emergency, The First Affiliated Hospital of Anhui Medical University, Hefei, China[14]Department of Emergency Medicine, The First Affiliated Hospital of SUN Yat-sen University, Guangzhou, China其他科室急诊科中山大学附属第一医院[15]Emergency Department, Second Hospital of Hebei Medical University, Shijiazhuang, China[16]Department of Emergency, First affiliated hospital of Nanjing Medical University, Nanjing, China门急诊科室急诊医学科江苏省人民医院[17]Department of Emergency, General Hospital of Ningxia Medical University, Yinchuan, China[18]Emergency Department, Tianjin Medical University General Hospital, Tianjin, China[19]Department of Emergency Medicine, Second Xiangya Hospital, Institute of Emergency Medicine and Difficult Diseases, Central South University, Changsha, China[20]Department of Emergency, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China[21]Department of Emergency, Cangzhou City Center Hospital, Cangzhou, China[22]Department of Emergency, First Hospital of Handan City, Handan, China[23]Pharmacology, Toxicology and Therapeutics, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
Background: Acute respiratory failure (ARF) is still one of the most severe complications in immunocompromised patients. Our previous systematic review showed noninvasive mechanical ventilation (NIV) reduced mortality, length of hospitalization and ICU stay in AIDS/hematological malignancy patients with relatively less severe ARF, compared to invasive mechanical ventilation (IMV). However, this systematic review was based on 13 observational studies and the quality of evidence was low to moderate. The efficacy of NIV in more severe ARF and in patients with other causes of immunodeficiency is still unclear. We aim to determine the efficacy of the initial ventilation strategy in managing ARF in immunocompromised patients stratified by different disease severity and causes of immunodeficiency, and explore predictors for failure of NIV. Methods and analysis: The VENIM is a multicentre randomized controlled trial (RCT) comparing the effects of NIV compared with IMV in adult immunocompromised patients with severe hypoxemic ARF. Patients who meet the indications for both forms of ventilatory support will be included. Primary outcome will be 30-day all-cause mortality. Secondary outcomes will include in-hospital mortality, length of stay in hospital, improvement of oxygenation, nosocomial infections, seven-day organ failure, adverse events of intervention, et al. Subgroups with different disease severity and causes of immunodeficiency will also be analyzed. Discussion: VENIM is the first randomized controlled trial aiming at assessing the efficacy of initial ventilation strategy in treating moderate and severe acute respiratory failure in immunocompromised patients. The result of this RCT may help doctors with their ventilation decisions.
基金:
VENIM is sponsored by the National Natural Science Foundation of China #
81550034 (Yi Li) and National Key Clinical Specialty Construction Program in
2012 (No. 20111204).
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类|3 区医学
小类|4 区呼吸系统
最新[2023]版:
大类|3 区医学
小类|3 区呼吸系统
第一作者:
第一作者机构:[1]Emergency Department, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Emergency Department, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China
推荐引用方式(GB/T 7714):
Tao Wang,Gang Liu,Kun He,et al.The efficacy of initial ventilation strategy for adult immunocompromised patients with severe acute hypoxemic respiratory failure: study protocol for a multicentre randomized controlled trial (VENIM)[J].BMC PULMONARY MEDICINE.2017,17(1):-.doi:10.1186/s12890-017-0467-6.
APA:
Tao Wang,Gang Liu,Kun He,Xin Lu,Xianquan Liang...&Xuezhong Yu.(2017).The efficacy of initial ventilation strategy for adult immunocompromised patients with severe acute hypoxemic respiratory failure: study protocol for a multicentre randomized controlled trial (VENIM).BMC PULMONARY MEDICINE,17,(1)
MLA:
Tao Wang,et al."The efficacy of initial ventilation strategy for adult immunocompromised patients with severe acute hypoxemic respiratory failure: study protocol for a multicentre randomized controlled trial (VENIM)".BMC PULMONARY MEDICINE 17..1(2017):-